Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Clinical Research of Mesylate Apatinib Combined With Docetaxel and S-1 as the First-line Treatment of Metastatic Gastric Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03154983
Recruitment Status : Recruiting
First Posted : May 16, 2017
Last Update Posted : October 19, 2017
Sponsor:
Collaborators:
Hubei Cancer Hospital
Huangshi Central Hospital
The Central Hospital of Huanggang
Xianning Central Hospital
Shiyan Taihe Hospital
The first hospital of Zaoyang
Hanchuan City people's Hospital
Yangxin People's Hospital
Tianmen People's Hospital
Information provided by (Responsible Party):
Zhou Fuxiang, Zhongnan Hospital

Brief Summary:
The purpose of this study is to evaluate the efficacy and safety of Apatinib Mesylate Tablets combined with docetaxel and S-1 as the first-line treatment of metastatic gastric cancer.

Condition or disease Intervention/treatment Phase
Metastatic Gastric Cancer Drug: docetaxel Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 48 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The Clinical Research of Mesylate Apatinib Combined With Docetaxel and S-1 as the First-line Treatment of Metastatic Gastric Cancer
Actual Study Start Date : May 20, 2017
Estimated Primary Completion Date : February 20, 2018
Estimated Study Completion Date : November 20, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Stomach Cancer
Drug Information available for: Docetaxel

Arm Intervention/treatment
Experimental: First-line treatment
First-line treatment:treatment including Mesylate Apatinib Combined With Docetaxel and S-1(DS).DS Docetaxel 75mg/m2 d1 iv.drop 1h(one hour), S-1(BSA<1.25 40mg Po bid(twice a day), BSA >=1.25-<1.5 50mg Po bid, BSA >=1.5 60mg Po bid), Q21d(21 days a cycle); Mesylate Apatinib 500mg Po QD(once a day) continuous use; until disease deterioration.
Drug: docetaxel
Diagnosed with metastatic gastric cancer patients (including the esophagogastric junction adenocarcinoma), DS(docetaxel and Tegafur)and Mesylate apatinib 6 cycles, the specific amount of usage: DS Docetaxel 75mg/m2 D1 IV.drop 1H(one hour), Tegafur(BSA<1.25 40mg Po bid(twice a day), BSA >=1.25-<1.5 50mg Po bid, BSA >=1.5 60mg Po bid, Q21d(21 days a cycle)); Mesylate Apatinib 500mg Po QD(once a day)) continuous use, until disease deterioration.
Other Names:
  • Tegafur
  • Mesylate Apatinib




Primary Outcome Measures :
  1. progress-free survival time [ Time Frame: 30 months ]
    During the treatment, the investigators will arrange patients to underwent CT and MRI examination on time, evaluating the size and the number of the tumor, to determine whether the disease progress than before; and the time from the start of treatment to the progression is progress-free survival time.


Secondary Outcome Measures :
  1. Overall survival Time [ Time Frame: 30 months ]
    During and after treatment, all patients were followed up regularly ,the patients will be arranged to evaluate the Performance status score or Karnofsky Performance Score to assess the patient's health and disease controling, until the patient died; the time from the beginning of treatment to death is overall survival time.

  2. Overall remission Rate [ Time Frame: during 6 cycles of chemotherapy (each cycle is 28 days) ]
    During the treatment, the investigators will regularly arrange patients to underwent CT, MRI ,Tumor marker examination and so on, evaluating the size and the number of the tumor, utilizing Response Evaluation Criteria in Solid Tumors to assess whether the disease progress than previous; and the percentage of patients with complete remission and partial remission of the disease is Overall remission Rate.

  3. adverse events [ Time Frame: up to 28 weeks ]
    During and after treatment, the investigators will on the basis of The clinical application expert consensus of Mesylate Apatinib to cure gastric cancer and The evaluation criteria of adverse drug reaction to assess patients who accepted treatment whether has adverse events.

  4. Quality of life [ Time Frame: 30 months ]
    During and after treatment, the investigators will on the basis of The Lancashire Quality of Life Profile to assess the patients' life quality regularly.

  5. disease control rate [ Time Frame: 30 months ]
    During the treatment, the investigators will regularly arrange patients to underwent CT, MRI ,Tumor marker examination and so on, to assess the size and the number of the tumor, utilizing Response Evaluation Criteria in Solid Tumors to assess whether the disease progress than previous; and the percentage of patients with disease control is disease control rate.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age: 18-70 years of age;
  2. recurrent or metastatic adenocarcinoma of the stomach or gastroesophageal junction diagnosed by pathology (including histology or cytology);
  3. 1 measurable lesions at least should be detected by CT/MRI examination in accordance with the RECIST(Response Evaluation Criteria In Solid Tumors)1.1;
  4. had not received other anti VEGFR targeted therapy;
  5. ECOG(Eastern Cooperative Oncology Group)PS(Performance Status):0-2 scores;
  6. the expected survival time is more than 3 months;
  7. if patient had accepted the chemotherapy, the time from the last chemotherapy should be more than 6 months;
  8. the damage caused by other treatments has been restored, and the subjects received radiotherapy or surgery over 4 weeks ago, and the wound has healed completely;
  9. the main organ function is normal, which should meet the following criteria: (1) blood routine examination standards should be met: (no blood transfusion within 14 days) A. HB(hemoglobin) = 90g/L, B. ANC(absolute neutrophil count) = 1.5 * 109/L, C. PLT(platelet) = 80 * 109/L; (2) biochemical examination shall comply with the following criteria: A. BIL(bilirubin) <1.25 normal upper limit (ULN), B. ALT(glutamic-pyruvic transaminase) and AST(glutamic-oxalacetic transaminase)<2.5ULN(upper limit of normal), if subjects have liver metastases, the ALT and AST <5ULN(upper limit of normal), C. Cr ≤ 1ULN, CCR(creatinine clearance rate) > 50ml/min (Cockcroft-Gault formula);
  10. women of childbearing age must have a pregnancy test in 7 days before entering the group (in serum), and the results were negative, and willing to use appropriate contraception during the study period and the last 8 weeks after giving drug test; men should have the surgical sterilization, or adopt the appropriate contraceptive methods during the test and the last 8 weeks after giving drug test;
  11. participants is willing to participate in this study, sign the informed consent, have good compliance, cooperate with follow-up.

Exclusion Criteria:

  1. Suffering from other malignant tumors previously or at the same time, with the exception of cured skin basal cell carcinoma and cervical carcinoma in situ;
  2. Patients have used the paclitaxel class and / or S-1 as the adjuvant therapy in 2;
  3. have been confirmed to be allergic to docetaxel, 5-fluorouracil, apatinib and / or its accessories;
  4. the blood pressure of patients with hypertension cannot be reduced to the normal range by the antihypertensive drugs (systolic pressure >140 mmHg, diastolic pressure >90 mmHg);
  5. patients are suffering from severe cardiovascular disease: the II level of myocardial ischemia or myocardial infarction, poor control of the arrhythmia (including QTc(corrected QT interval) prolongation of male > 450 ms, of female > 470ms ); and patients have III-IV grade of cardiac insufficiency, or left ventricular (LVEF) < 50% shown by echocardiography according to the NYHA(New York Heart Association) standard;
  6. patients are positive of urine protein (urine protein detection 2+ or above, or 24 hours urine protein quantitative >1.0g);
  7. have a variety of factors that affect oral drugs (such as difficulty in swallowing, nausea, vomiting, chronic diarrhea and intestinal obstruction, etc.);
  8. patients have a clear tendency with gastrointestinal bleeding, including the following situation: local active ulcerative lesions, and fecal occult blood (+ +); with melena and hematemesis history in 2 months; and patients with fecal occult blood (+) and unresected gastric primary tumor; patients with the risk of bleeding should take the gastroscopy test, if it is the gastric cancer, and researchers believe that may results in massive digestive tract hemorrhage;
  9. coagulation dysfunction (INR(international normalized ratio)>1.5, APTT(activated partial thromboplastin time)>1.5 ULN), with bleeding tendency;
  10. patients with a history of psychotropic substance abuse and unable to give up or have mental disorders;
  11. Patients who participated in other clinical trials within 4 weeks;
  12. have received the VEGFR inhibitors, such as sorafenib and sunitinib;
  13. according to the researcher's judgment, there are other accompanying disease endangering the patient's safety or affect the patient to complete the study.
  14. patients with central nervous system metastasis;
  15. pregnant or lactating women;
  16. the researchers consider those who were not suitable for inclusion.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03154983


Contacts
Layout table for location contacts
Contact: Ling Xia, M.D. 18971250716 82425583@qq.com

Locations
Layout table for location information
China, Hubei
Zhongnan Hospital of Wuhan University Recruiting
Wuhan, Hubei, China
Contact: Fuxiang Zhou, M.D.    18971252780    happyzhoufx@sina.com   
Contact: Ling Xia, M.D.    18971250716    82425583@qq.com   
Sponsors and Collaborators
Zhou Fuxiang
Hubei Cancer Hospital
Huangshi Central Hospital
The Central Hospital of Huanggang
Xianning Central Hospital
Shiyan Taihe Hospital
The first hospital of Zaoyang
Hanchuan City people's Hospital
Yangxin People's Hospital
Tianmen People's Hospital
Investigators
Layout table for investigator information
Study Chair: Fuxiang Zhou, M.D. Wuhan University

Layout table for additonal information
Responsible Party: Zhou Fuxiang, Director, Zhongnan Hospital
ClinicalTrials.gov Identifier: NCT03154983     History of Changes
Other Study ID Numbers: HCCSC G04
First Posted: May 16, 2017    Key Record Dates
Last Update Posted: October 19, 2017
Last Verified: October 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Zhou Fuxiang, Zhongnan Hospital:
Mesylate Apatinib
The First-line Treatment
Metastatic Gastric Cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Stomach Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Stomach Diseases
Docetaxel
Apatinib
Tegafur
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Protein Kinase Inhibitors
Enzyme Inhibitors
Antimetabolites, Antineoplastic
Antimetabolites